FDA & Government News

July 17, 2026

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

Conexiant

July 16, 2026

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Conexiant

July 16, 2026

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

Conexiant

July 15, 2026

FDA Classifies Medtronic Harmony Recall as Class I

Distal tip detachment during implantation may necessitate retrieval of the detached tip through an endovascular or surgical procedure.

Conexiant

July 13, 2026

New CDC Report Tracks US Mortality Trends

The annual provisional report summarizes changes in mortality rates, demographic patterns, and leading causes of death during 2025.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

July 10, 2026

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

Conexiant

July 08, 2026

FDA Approves Dual-Energy Catheter Ablation Platform

The platform integrates with the CARTO ecosystem and enables physicians to use either pulsed field or radiofrequency energy based on patient anatomy and case complexity.

Conexiant

June 26, 2026

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

June 24, 2026

FDA Approves First Therapy to Reduce Pancreatitis Risk

In two placebo-controlled trials, triglyceride levels declined by up to 72% compared with placebo.

Conexiant

June 22, 2026

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

Conexiant

FDA Approves First Oral PCSK9 Inhibitor

FDA & Government News

FDA Approves New Iohexol Vials

FDA Approves First Oral PCSK9 Inhibitor

Oral Aleniglipron Reduced Weight at 36 Weeks

FDA Classifies Medtronic Harmony Recall as Class I

New CDC Report Tracks US Mortality Trends

Daily News

10 CMS and FDA Actions Affecting Care in 2026

FDA Approves Dual-Energy Catheter Ablation Platform

FDA Monthly Preview: Key July Decisions to Watch

FDA Approves First Therapy to Reduce Pancreatitis Risk

FDA Cites Manufacturing Issues for Cytisinicline

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

FDA Approves First Oral PCSK9 Inhibitor

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dentistry

ADA News

CDE World

New Dentist News

Conexiant

AACE Endocrinology AI

Conexiant

GI & Hepatology News

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

FDA & Government News

Daily News

Recommendations